Viatris (VTRS) Cash & Current Investments (2019 - 2026)
Viatris' (VTRS) quarterly Cash & Current Investments came in at $1.8 billion in Q1 2026, up 138.97% year-on-year from $755.0 million in Q1 2025, and up 36.43% quarter-over-quarter from $1.3 billion in Q4 2025.
Viatris (VTRS) Cash & Current Investments (2019 - 2026) Analysis & Trends
Viatris' Cash & Current Investments history runs 8 years deep, the most recent figure standing at $1.8 billion for Q1 2026.
- On a quarterly basis, Cash & Current Investments rose 138.97% year-over-year to $1.8 billion in Q1 2026; TTM through Mar 2026 was $1.8 billion, a 138.97% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 79.65% from the prior year.
- Cash & Current Investments advanced to $1.8 billion in Q1 2026 per VTRS's latest filing, from $1.3 billion in the prior quarter.
- Across five years, Cash & Current Investments topped out at $1.9 billion in Q3 2024 and bottomed at $506.6 million in Q1 2023.
- The 5-year median for Cash & Current Investments is $917.2 million (2024), against an average of $984.3 million.
- Across the five-year window, Cash & Current Investments slumped 48.09% in 2025 and jumped 138.97% in 2026, its largest moves.
- Year by year, Cash & Current Investments stood at $1.3 billion in 2022, then declined by 21.43% to $991.9 million in 2023, then retreated by 25.79% to $736.1 million in 2024, then jumped by 79.65% to $1.3 billion in 2025, then soared by 36.43% to $1.8 billion in 2026.
- Per Business Quant, the three latest VTRS Cash & Current Investments figures stand at $1.8 billion (Q1 2026), $1.3 billion (Q4 2025), and $975.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 35.81 Bn | 32.07 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 23.19 Bn | 21.04 Bn | 648.10 Mn | 2.15 Bn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.47 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.72 Bn | 16.40 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.56 Bn | 12.13 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn | 153.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.80 Bn |
| Dec 31, 2025 | 1.32 Bn |
| Sep 30, 2025 | 975.30 Mn |
| Jun 30, 2025 | 566.40 Mn |
| Mar 31, 2025 | 755.00 Mn |
| Dec 31, 2024 | 736.10 Mn |
| Sep 30, 2024 | 1.88 Bn |
| Jun 30, 2024 | 917.20 Mn |
| Mar 31, 2024 | 1.01 Bn |
| Dec 31, 2023 | 991.90 Mn |
| Sep 30, 2023 | 1.31 Bn |
| Jun 30, 2023 | 629.20 Mn |
| Mar 31, 2023 | 506.60 Mn |
| Dec 31, 2022 | 1.26 Bn |
| Sep 30, 2022 | 646.70 Mn |
| Jun 30, 2022 | 664.70 Mn |
| Mar 31, 2022 | 752.40 Mn |
| Dec 31, 2021 | 706.20 Mn |
| Sep 30, 2021 | 756.60 Mn |
| Jun 30, 2021 | 673.90 Mn |